Articles tagged with Breast Cancer
Melanie Rutkowski's pioneering research may lead to novel immunotherapy treatments for ovarian cancer by understanding how faulty cellular signaling interacts with the microbiome. The grant aims to enhance immune system's ability to kill cancer cells and improve patient outcomes.
Researchers found that pitavastatin directly inhibits the anti-apoptotic protein Mcl-1, a key driver of survival and resistance in TNBC cells. The study showed pitavastatin effectively eliminates cancer stem-like cell populations and reduces tumor growth, angiogenesis, and lung metastasis.
The Global Centre for Asian Women’s Health has partnered with NUS Medicine to host the Women’s Health Impact Tracking (WHIT) platform, which measures progress on closing the women’s health gap across a set of conditions and countries. The platform provides clear, comparative insights to support decision-making and inform policies.
A new study found that a drug mimicking the hormone progesterone, megestrol, has anti-cancer activity when used with conventional anti-oestrogen treatment for women with breast cancer. This combination showed a greater decrease in tumour growth rates compared to those treated with an anti-oestrogen only.
A large-scale international study has deciphered a mechanism enabling breast cancer to metastasize to the brain. Researchers identified a specific chromosomal alteration predicting high likelihood of brain metastases and found that the absence of functional p53 gene impairs brain environment adaptation.
Researchers discover breast cancer cells hijack the immune system's alarm pathway, inducing chronic pro-tumor inflammation. This shift creates a vulnerability that can be targeted by existing immunotherapies.
A survey study found that exposure to medical misinformation was common among breast cancer patients, yet fear of recurrence was not associated. Further research on how patients process medical misinformation is essential to improve survivorship communication and reduce misinformation spread.
Researchers at OHSU discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome treatment resistance by pairing venetoclax, a standard AML drug, with palbociclib, a cell-cycle inhibitor approved for breast cancer. The study found that this combination produced significantly stronger and m...
Researchers highlight how minimal residual disease detection is changing breast cancer management by capturing molecular traces of cancer at extremely low levels. CTDNA-based monitoring reveals relapse risk months ahead of clinical symptoms, enabling clinicians to identify high-risk patients and adjust treatment strategies in real time.
Researchers have identified Rb1 as a predictive biomarker for a new therapeutic strategy in some breast cancers. The study found that simultaneous inhibition of ATR and PKMYT1 triggers cell death in Rb1-deficient breast cancer models, leading to tumor shrinkage and improved survival.
A new study from Texas A&M University reveals that circadian disruptions change the structure of mammary glands, weaken immune defenses, and fuel aggressive breast cancer. Disabling an immune checkpoint molecule called LILRB4 helps restore the immune system's ability to fight back.
A deep learning framework called PRTS accurately predicts single-cell-resolution spatial transcriptomics from H&E-stained histology images. The model identifies 21 cell subtypes in mouse brain and maintains prediction accuracy in human breast and lung cancer tissues.
UT Health San Antonio received $3 million in CPRIT grants to expand access to preventive salpingectomy, test novel methods to prevent liver cancer, and advance treatment for therapy-resistant metastatic breast cancer. These projects aim to improve cancer prevention, diagnosis, and treatment in South Texas.
A new study has found that radioactive seed localization (RSL) is an effective and comfortable alternative to traditional wire localization for breast cancer surgery. Patients who received RSL reported less pain and anxiety, while surgeons rated the technique as more convenient and satisfying to perform.
Proton therapy has been shown to provide a significant survival benefit for patients with head and neck cancers. In another study, researchers have identified a promising target for treating pancreatic cancer by inhibiting the mitochondrial enzyme GFER. Additionally, diagnostic breast MRI may be unnecessary for some patients with early...
A study from Rutgers Cancer Institute researchers found that Black women with breast cancer who ate the most ultra-processed foods before diagnosis were 36-40% more likely to die from their cancers or other causes of death. The researchers followed 1,733 Black women diagnosed with breast cancer in New Jersey between 2005 and 2019.
A randomized controlled pilot study investigates the effects of Baduanjin exercise on menopausal symptoms in breast cancer patients taking aromatase inhibitors. The study reveals that Baduanjin alleviates hot flash severity and improves quality of life for these women.
Studies show that patients with advanced ovarian and metastatic breast cancer dedicate approximately 7 hours per week to cancer-related tasks. Most participants report performing these tasks daily, impacting their time burden. The use of a mobile app facilitated the collection of detailed time-use data.
Research found that breast cancer flattens corticosterone release in mice, reducing quality of life and increasing mortality. Disruptions to diurnal rhythms have been linked to stress responses like insomnia and anxiety in cancer patients.
Dr Aldona Mzyk's project uses quantum sensors to track how immune cells interact with tumours, enabling the development of improved patient-tailored cancer therapies and earlier diagnosis tools. The research aims to overcome current cancer immunotherapies' failure in solid tumours by controlling metabolic changes.
A matched prospective analysis of 676 women found that menopausal hormone therapy was not associated with an increased risk of breast cancer in those with BRCA mutations. This suggests a personalized approach to menopause management for these women, balancing the risks and benefits of MHT use.
Breast cancer survivors experienced significant improvement in perceived cognitive impairment with real acupuncture, outperforming sham acupuncture and usual care. Real acupuncture also showed benefits in objective cognitive function, particularly when compared to sham acupuncture.
A mobile health intervention, Young, Empowered & Strong (YES), improved quality of life and symptoms in adolescent and young adult breast cancer survivors. The study found significant reductions in general and cancer-specific quality of life scores after six months.
The WISDOM randomized clinical trial found risk-based breast cancer screening to be equally effective as annual screening in detecting advanced cancers. However, it did not reduce breast biopsy rates. The study suggests a safer and more efficient approach to breast cancer screening.
A secondary analysis of the WISDOM trial found a substantial number of women with clinically actionable genetic variants, many not qualifying for current guidelines. This study supports broader access to genetic testing for personalized breast cancer risk assessment.
Maher El-Kady's work on sustainable energy storage technologies aims to create a cleaner, more accessible future. Dr. Dennis Slamon's breakthroughs in breast cancer treatment have benefited millions worldwide, highlighting the impact of UCLA researchers on global health and innovation.
A recent study found that preoperative breast MRI did not significantly impact five-year recurrence rates or overall survival in patients with stage 1 or 2, hormone receptor-negative breast cancer. The trial involved 319 patients and showed similar results between those who underwent MRI and those who did not.
A phase II clinical trial found that preoperative radiation improved T-cell infiltration and treatment responses in hormone receptor-positive, HER2-negative breast cancer patients. Radiation doses of 24 Gy showed the greatest increase in TCI and tumor clearance, suggesting a potential new strategy for immunotherapy.
Research from Florida Atlantic University strengthens evidence that alcohol consumption increases cancer risk, particularly for breast, colorectal, and liver cancers. Higher intake and specific groups, such as African Americans and those with obesity or diabetes, are found to be more vulnerable to the risks.
A recent study found that omitting sentinel lymph node biopsy (SLNB) in clinically node-negative, HR-positive, HER2-negative early-stage breast cancer patients did not compromise regional control or survival after a median five years of follow-up. The recurrence of the cancer in the lymph nodes surrounding the primary tumor was observe...
A prospective multicenter trial validated an improved method for predicting treatment benefits in hormone receptor-positive metastatic breast cancer with bone metastases. Metabolic change assessed by FDG-PET/CT accurately predicted progression-free survival as early as 12 weeks after treatment initiation.
The study found that the investigational vaccine produced an immune response in 74% of participants and was safe and well-tolerated. A Phase 2 study is planned to evaluate the vaccine's efficacy, offering new hope for triple-negative breast cancer treatment.
A new oral endocrine therapy, giredestrant, has been shown to significantly lower the risk of breast cancer recurrence in early-stage HR-positive/HER2-negative patients. In a large clinical trial, patients treated with giredestrant were 30% less likely to have invasive disease recur or progress.
The addition of tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab delayed disease progression in HER2-positive metastatic breast cancer patients, particularly those with brain metastasis. This delay allowed for prolonged time off chemotherapy and maintained disease control.
For patients with HR-positive, HER2-negative advanced breast cancers who have received endocrine therapy, sacituzumab govitecan-hziy offers comparable progression-free survival rates as standard chemotherapy. The study also found higher response rates and longer response durations for patients treated with sacituzumab govitecan-hziy.
The phase III lidERA trial found that giredestrant improved invasive disease-free survival compared to standard-of-care endocrine therapy. Patients who received giredestrant were 30% less likely to develop invasive disease progression and had a clinically meaningful superiority to currently established endocrine agents.
A new AI model has been developed to improve the accuracy of recurrence risk stratification in hormone receptor-positive, HER2-negative breast cancer. The model, called ICM+, uses a combination of clinical, molecular, and histopathological data to provide better prognostic information about cancer recurrence risk out to 15 years.
Researchers developed multimodal models integrating imaging, clinical, and molecular data from TAILORx tissue biorepository for early-stage breast cancer. The models demonstrated enhanced prognostic performance compared to existing methods, highlighting their potential for personalized treatment decision-making.
Researchers from Mount Sinai present new discoveries in breast cancer biology, treatment, and real-world patient outcomes. The institution's contributions span artificial intelligence, triple-negative breast cancer, geriatric oncology, and novel therapeutic approaches.
Researchers mapped NBCn1's structure-function properties to understand how breast cancer cells thrive in hostile environments. The study provides insights into the protein's dynamics and ion transport pathways, paving the way for designing drugs that target this transporter.
Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.
The 48th San Antonio Breast Cancer Symposium brings together over 10,000 global experts to share cutting-edge research on breast cancer discovery, therapeutics, and standard of care. Key findings include the effectiveness of active monitoring for low-risk DCIS patients and a new estrogen-blocking pill that slows cancer progression.
Researchers at UCLA present several new studies on emerging blood-based surveillance tools, new approaches to predicting treatment response, and tailoring therapies across the disease spectrum for patients with breast cancer. The findings highlight the potential of precision medicine in improving quality of life.
A new study developed an antibody that blocks several ways TNBC cells survive, grow, and evade the immune system. The antibody suppressed primary tumor growth and reenergized cancer-fighting immune cells, including T-cells and macrophages, in preclinical models.
Researchers discovered breast cancer modifies lymphatic vessels to facilitate its spread. A specific protein, Matrix Gla protein (MPG), enables cancer cells to bind to lymphatic vessels, supporting metastasis. Understanding this process could lead to targeted therapies and improved patient outcomes.
A new study published in the Journal of the American College of Radiology found that targeted outreach can increase lung cancer screenings for eligible women who undergo mammograms. The CALM model, which coordinates lung screening with mammography, exceeded its target enrollment and demonstrated effectiveness in increasing uptake. By i...
A new study found that breast density notifications can lead to increased levels of confusion and anxiousness among women, contradicting the intended goal of empowering them. Women with denser breast tissue may require additional screening methods, which can result in higher out-of-pocket costs.
Researchers found that women notified of their dense breasts felt more anxious and confused about their breast health, with increased intentions to talk to their GP. The study suggests that population breast density notification should be carefully considered due to potential adverse outcomes.
Researchers found estrone hormone drives inflammatory activity in postmenopausal women with obesity, increasing risk of aggressive breast cancer. Lifestyle interventions may not be sustainable, but GLP-1 drugs show promise as a therapy.
Omomyc, a direct MYC inhibitor, causes DNA damage in cancer cells and potentiates antitumor response when combined with PARPi inhibitors. This synergy offers a new therapeutic opportunity to overcome PARPi resistance in triple-negative breast cancer.
A study of seven outpatient facilities found that 20-24% of all breast cancers diagnosed between 2014 and 2024 were in women aged 18-49. Invasive cancer cases accounted for 80.7%, often with aggressive types, challenging age-based screening cutoffs.
Serum markers such as NLR, PLR, ESR, LDH, ALP, creatine kinase-BB, SUA, CRP, and CA 15-3/27.29 have been linked to breast cancer diagnosis, prognosis, and therapeutic monitoring. These biomarkers offer affordable, non-invasive, and accessible diagnostic strategies for bridging the diagnostic gap in low-resource settings.
A new AI image-only model has been shown to provide stronger and more precise risk stratification for five-year breast cancer prediction than traditional breast density assessment. The model was trained on 421,499 mammograms and showed a fourfold higher cancer incidence in high-risk women compared to those with average risk.
The new system can reveal early cancers, lung disease, hidden material defects and changes in porosity without multiple exposures or complex mechanical movement. This method produces low-dose and faster images, lowering patients' radiation dose and making clinical translation feasible.
Researchers discovered that synthetic stress hormone dexamethasone can combat therapy-resistant breast cancer metastases in mice trials. The drug activates the glucocorticoid receptor, suppressing estrogen receptor production and slowing tumor growth. Further studies are needed to confirm these findings in patients with breast cancer.
Researchers at the LSU LCMC Health Cancer Center have identified key immune differences in triple-negative breast cancer, a leading cause of breast cancer deaths among Black women. The study provides new insights that could lead to more effective and personalized treatments for this aggressive form of cancer.
A new study using magnetoelectric nanoparticles successfully shrinks pancreatic tumors in preclinical models, extending survival. The Sylvester Cancer Institute has also launched its Survivorship and Supportive Care Institute to provide evidence-based care for cancer patients.
Researchers have discovered a new class of BRCA1 mutations that can be targeted by HSP90 inhibitors, potentially improving treatment outcomes for patients with breast cancer. The study found that these mutations are more resistant to PARP inhibitor treatment but can be overcome with low-dose HSP90 inhibition.
Researchers at UC San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer (TNBC), employing an antibody-drug conjugate to deliver chemotherapy directly into cancer cells. Targeting tumor-initiating cells through FZD7 may offer a path forward for patients with aggressive TNBC that fails to ...
Dr. Sedrak receives King Hussein Cancer Research Award for innovative work on accelerated aging in cancer survivors, with a focus on developing new strategies to prevent or reverse age-related effects. His research aims to improve health span and quality of life for cancer patients, holding promise for other age-related diseases.